Paul D Bieniasz

List of Publications by Year
in descending order

174 papers	33,318 citations	5261 83 h-index	4770 169 g-index
220 all docs	220 docs citations	220 times ranked	31510 citing authors

#	Article	IF	Citations
1	Poly(ADP-ribose) potentiates ZAP antiviral activity. PLoS Pathogens, 2022, 18, e1009202.	2.1	19
2	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. New England Journal of Medicine, 2022, 386, 599-601.	13.9	371
3	Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting. PLoS ONE, 2022, 17, e0266086.	1.1	6
4	VPS29 Exerts Opposing Effects on Endocytic Viral Entry. MBio, 2022, 13, e0300221.	1.8	5
5	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity, 2022, 55, 998-1012.e8.	6.6	86
6	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature, 2022, 607, 128-134.	13.7	197
7	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
8	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. Lancet Microbe, The, 2022, 3, e493-e502.	3.4	22
9	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. MBio, 2022, 13, .	1.8	9
10	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. Journal of Experimental Medicine, 2022, 219, .	4.2	10
11	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. Journal of Experimental Medicine, 2022, 219, .	4.2	6
12	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. Clinical Infectious Diseases, 2021, 73, e1208-e1211.	2.9	65
13	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. Journal of Infectious Diseases, 2021, 223, 389-398.	1.9	233
14	Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science Translational Medicine, 2021, 13, .	5.8	379
15	Mechanisms of Attenuation by Genetic Recoding of Viruses. MBio, 2021, 12, .	1.8	12
16	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	13.7	1,355
17	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	13.7	1,232
18	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature, 2021, 593, 424-428.	13.7	108

#	Article	IF	Citations
19	Origin and evolution of the zinc finger antiviral protein. PLoS Pathogens, 2021, 17, e1009545.	2.1	33
20	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature, 2021, 595, 426-431.	13.7	610
21	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell, 2021, 184, 3205-3221.e24.	13.5	73
22	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature, 2021, 595, 278-282.	13.7	154
23	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine, 2021, 384, 2212-2218.	13.9	647
24	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. PLoS Pathogens, 2021, 17, e1009688.	2.1	16
25	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nature Communications, 2021, 12, 4196.	5.8	332
26	Derivation and characterization of an HIV-1 mutant that rescues IP6 binding deficiency. Retrovirology, 2021, 18, 25.	0.9	7
27	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 2021, 54, 1853-1868.e7.	6.6	230
28	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	2.9	80
29	HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. Cell Host and Microbe, 2021, 29, 1421-1436.e7.	5.1	22
30	Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerging Infectious Diseases, 2021, 27, 2454-2458.	2.0	48
31	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. Journal of Clinical Virology Plus, 2021, 1, 100028.	0.4	2
32	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature, 2021, 600, 512-516.	13.7	174
33	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Reports Medicine, 2021, 2, 100164.	3.3	26
34	The Case Against Delaying Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine Boosting Doses. Clinical Infectious Diseases, 2021, 73, 1321-1323.	2.9	22
35	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine, 2021, 218, .	4.2	283
36	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	13.7	239

#	Article	IF	Citations
37	Replication and single-cycle delivery of SARS-CoV-2 replicons. Science, 2021, 374, 1099-1106.	6.0	49
38	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature Immunology, 2021, 22, 1503-1514.	7.0	40
39	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. ELife, 2021, 10, .	2.8	36
40	Inhibition of spumavirus gene expression by PHF11. PLoS Pathogens, 2020, 16, e1008644.	2.1	11
41	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	13.7	1,742
42	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine, 2020, 217, .	4.2	503
43	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. Journal of Clinical Microbiology, 2020, 58, .	1.8	154
44	Determination of RNA structural diversity and its role in HIV-1 RNA splicing. Nature, 2020, 582, 438-442.	13.7	136
45	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell, 2020, 182, 828-842.e16.	13.5	724
46	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. Cell Host and Microbe, 2020, 27, 963-975.e5.	5.1	23
47	HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. ELife, 2020, 9, .	2.8	37
48	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. ELife, 2020, 9, .	2.8	1,239
49	Genome-Wide Analysis of Heterogeneous Nuclear Ribonucleoprotein (hnRNP) Binding to HIV-1 RNA Reveals a Key Role for hnRNP H1 in Alternative Viral mRNA Splicing. Journal of Virology, 2019, 93, .	1.5	19
50	Structure of the zinc-finger antiviral protein in complex with RNA reveals a mechanism for selective targeting of CG-rich viral sequences. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24303-24309.	3.3	106
51	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10504-10509.	3.3	14
52	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. PLoS Pathogens, 2019, 15, e1007632.	2.1	20
53	Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State. Journal of Virology, 2019, 93, .	1.5	28
54	Short Communication: Ultrasensitive Immunoassay for Assessing Residual Simian-Tropic HIV in Nonhuman Primate Models of AIDS. AIDS Research and Human Retroviruses, 2019, 35, 473-476.	0.5	0

#	Article	IF	Citations
55	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. ELife, 2019, 8, .	2.8	6
56	A multimodal antiretroviral protein. Nature Microbiology, 2018, 3, 122-123.	5.9	3
57	Multiple, Switchable Protein:RNA Interactions Regulate Human Immunodeficiency Virus Type 1 Assembly. Annual Review of Virology, 2018, 5, 165-183.	3.0	50
58	Reconstruction of a replication-competent ancestral murine endogenous retrovirus-L. Retrovirology, 2018, 15, 34.	0.9	11
59	CLIP-related methodologies and their application to retrovirology. Retrovirology, 2018, 15, 35.	0.9	12
60	Global synonymous mutagenesis identifies cis-acting RNA elements that regulate HIV-1 splicing and replication. PLoS Pathogens, 2018, 14, e1006824.	2.1	37
61	Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. ELife, 2018, 7, .	2.8	100
62	The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression. ELife, 2018, 7, .	2.8	27
63	Tetherin Inhibits Cell-Free Virus Dissemination and Retards Murine Leukemia Virus Pathogenesis. Journal of Virology, 2017, 91, .	1.5	16
64	Repurposing a Bacterial Immune System to Discover Antiviral Targets. New England Journal of Medicine, 2017, 376, 1290-1291.	13.9	3
65	CG dinucleotide suppression enables antiviral defence targeting non-self RNA. Nature, 2017, 550, 124-127.	13.7	336
66	A single gp120 residue can affect HIV-1 tropism in macaques. PLoS Pathogens, 2017, 13, e1006572.	2.1	28
67	Co-option of an endogenous retrovirus envelope for host defense in hominid ancestors. ELife, 2017, 6, .	2.8	75
68	The RNA Binding Specificity of Human APOBEC3 Proteins Resembles That of HIV-1 Nucleocapsid. PLoS Pathogens, 2016, 12, e1005833.	2.1	54
69	HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis. Cell, 2016, 166, 1257-1268.e12.	13.5	110
70	Identification of Interferon-Stimulated Genes with Antiretroviral Activity. Cell Host and Microbe, 2016, 20, 392-405.	5.1	215
71	Origins and Evolution of tetherin , an Orphan Antiviral Gene. Cell Host and Microbe, 2016, 20, 189-201.	5.1	35
72	Analysis of the human immunodeficiency virus-1 RNA packageome. Rna, 2016, 22, 1228-1238.	1.6	46

#	Article	IF	Citations
73	Single-Cell and Single-Cycle Analysis of HIV-1 Replication. PLoS Pathogens, 2015, 11, e1004961.	2.1	58
74	A Serpin Shapes the Extracellular Environment to Prevent Influenza A Virus Maturation. Cell, 2015, 160, 631-643.	13.5	137
75	Uneven Genetic Robustness of HIV-1 Integrase. Journal of Virology, 2015, 89, 552-567.	1.5	20
76	Temporal and spatial organization of ESCRT protein recruitment during HIV-1 budding. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12211-12216.	3.3	93
77	Tetherin Promotes the Innate and Adaptive Cellâ€"Mediated Immune Response against Retrovirus Infection In Vivo. Journal of Immunology, 2014, 193, 306-316.	0.4	45
78	Global Changes in the RNA Binding Specificity of HIV-1 Gag Regulate Virion Genesis. Cell, 2014, 159, 1096-1109.	13.5	216
79	Host and Viral Determinants of Mx2 Antiretroviral Activity. Journal of Virology, 2014, 88, 7738-7752.	1.5	144
80	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. Cell Host and Microbe, 2014, 16, 412-418.	5.1	47
81	HIV-1â€"induced AIDS in monkeys. Science, 2014, 344, 1401-1405.	6.0	76
82	SAMHD1-dependent retroviral control and escape in mice. EMBO Journal, 2013, 32, 2454-2462.	3.5	141
83	MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature, 2013, 502, 563-566.	13.7	445
84	Vpu Binds Directly to Tetherin and Displaces It from Nascent Virions. PLoS Pathogens, 2013, 9, e1003299.	2.1	102
85	Mechanism of HIV-1 Virion Entrapment by Tetherin. PLoS Pathogens, 2013, 9, e1003483.	2.1	97
86	Extreme Genetic Fragility of the HIV-1 Capsid. PLoS Pathogens, 2013, 9, e1003461.	2.1	178
87	Assisted Evolution Enables HIV-1 to Overcome a High TRIM5Î±-Imposed Genetic Barrier to Rhesus Macaque Tropism. PLoS Pathogens, 2013, 9, e1003667.	2.1	32
88	Fates of Retroviral Core Components during Unrestricted and TRIM5-Restricted Infection. PLoS Pathogens, 2013, 9, e1003214.	2.1	82
89	Adaptation to the Interferon-Induced Antiviral State by Human and Simian Immunodeficiency Viruses. Journal of Virology, 2013, 87, 3549-3560.	1.5	28
90	HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006940-a006940.	2.9	421

#	Article	IF	Citations
91	An overview of intracellular interactions between immunodeficiency viruses and their hosts. Aids, 2012, 26, 1243-1254.	1.0	18
92	Inhibition of HIV-1 Particle Assembly by 2â€²,3â€²-Cyclic-Nucleotide 3â€²-Phosphodiesterase. Cell Host and Microbe, 2012, 12, 585-597.	5.1	54
93	Intrinsic Cellular Defenses against Human Immunodeficiency Viruses. Immunity, 2012, 37, 399-411.	6.6	96
94	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 2012, 492, 118-122.	13.7	463
95	Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18097-18101.	3.3	112
96	Antiretroviral restriction factors. Current Opinion in Virology, 2011, 1, 526-532.	2.6	32
97	Visualizing HIV-1 Assembly. Journal of Molecular Biology, 2011, 410, 501-511.	2.0	73
98	Dynamics of ESCRT protein recruitment during retroviral assembly. Nature Cell Biology, 2011, 13, 394-401.	4.6	198
99	A diverse range of gene products are effectors of the type I interferon antiviral response. Nature, 2011, 472, 481-485.	13.7	2,054
100	Sensing Retroviruses. Immunity, 2011, 35, 8-10.	6.6	2
101	Clathrin Facilitates the Morphogenesis of Retrovirus Particles. PLoS Pathogens, 2011, 7, e1002119.	2.1	45
102	SIV Nef Proteins Recruit the AP-2 Complex to Antagonize Tetherin and Facilitate Virion Release. PLoS Pathogens, 2011, 7, e1002039.	2.1	59
103	Identification of a receptor for an extinct virus. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19496-19501.	3.3	27
104	Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18428-18432.	3.3	97
105	Functional Interchangeability of Late Domains, Late Domain Cofactors and Ubiquitin in Viral Budding. PLoS Pathogens, 2010, 6, e1001153.	2.1	57
106	The RING-CH Ligase K5 Antagonizes Restriction of KSHV and HIV-1 Particle Release by Mediating Ubiquitin-Dependent Endosomal Degradation of Tetherin. PLoS Pathogens, 2010, 6, e1000843.	2.1	129
107	Analysis of the Initiating Events in HIV-1 Particle Assembly and Genome Packaging. PLoS Pathogens, 2010, 6, e1001200.	2.1	162
108	Human Immunodeficiency Virus, Restriction Factors, and Interferon. Journal of Interferon and Cytokine Research, 2009, 29, 569-580.	0.5	116

#	Article	IF	Citations
109	Integration target site selection by a resurrected human endogenous retrovirus. Genes and Development, 2009, 23, 633-642.	2.7	95
110	A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. Journal of Cell Biology, 2009, 184, 881-894.	2.3	120
111	Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin. Journal of Virology, 2009, 83, 1837-1844.	1.5	347
112	Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19114-19119.	3.3	233
113	Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants. PLoS Pathogens, 2009, 5, e1000300.	2.1	273
114	A macaque model of HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4425-4429.	3.3	150
115	Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells. Cell, 2009, 139, 499-511.	13.5	517
116	Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin Antagonists. Cell Host and Microbe, 2009, 6, 54-67.	5.1	324
117	The Cell Biology of HIV-1 Virion Genesis. Cell Host and Microbe, 2009, 5, 550-558.	5.1	175
118	Tetherin-Driven Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains. Cell Host and Microbe, 2009, 6, 409-421.	5.1	391
119	Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 2008, 451, 425-430.	13.7	1,618
120	Imaging the biogenesis of individual HIV-1 virions in live cells. Nature, 2008, 454, 236-240.	13.7	290
121	No effect of endogenous TRIM5Î± on HIV-1 production. Nature Medicine, 2008, 14, 235-236.	15.2	35
122	HIV-1 at 25. Cell, 2008, 133, 561-565.	13.5	43
123	Evidence for Restriction of Ancient Primate Gammaretroviruses by APOBEC3 but Not TRIM5Î± Proteins. PLoS Pathogens, 2008, 4, e1000181.	2.1	33
124	Hypermutation of an Ancient Human Retrovirus by APOBEC3G. Journal of Virology, 2008, 82, 8762-8770.	1.5	84
125	Primate Lentivirus Capsid Sensitivity to TRIM5 Proteins. Journal of Virology, 2008, 82, 6772-6777.	1.5	51
126	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3563-3568.	3.3	183

#	Article	IF	Citations
127	Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20031-20036.	3.3	77
128	Reconstitution of an Infectious Human Endogenous Retrovirus. PLoS Pathogens, 2007, 3, e10.	2.1	249
129	An Interferon-Î±-Induced Tethering Mechanism Inhibits HIV-1 and Ebola Virus Particle Release but Is Counteracted by the HIV-1 Vpu Protein. Cell Host and Microbe, 2007, 2, 193-203.	5.1	241
130	Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature, 2007, 446, 801-805.	13.7	1,082
131	HIV/AIDS: in search of an animal model. Trends in Biotechnology, 2007, 25, 333-337.	4.9	72
132	An intrinsic host defense against HIV-1 integration?. Journal of Clinical Investigation, 2007, 117, 302-304.	3.9	8
133	Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology, 2006, 349, 31-40.	1.1	88
134	Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion. Science, 2006, 314, 95-95.	6.0	140
135	Plasma Membrane Is the Site of Productive HIV-1 Particle Assembly. PLoS Biology, 2006, 4, e435.	2.6	299
136	Effect of DNA Repair Protein Rad18 on Viral Infection. PLoS Pathogens, 2006, 2, e40.	2.1	32
137	HIV-1 Vpu Promotes Release and Prevents Endocytosis of Nascent Retrovirus Particles from the Plasma Membrane. PLoS Pathogens, 2006, 2, e39.	2.1	239
138	The Betaretrovirus Mason-Pfizer Monkey Virus Selectively Excludes Simian APOBEC3G from Virion Particles. Journal of Virology, 2006, 80, 12102-12108.	1.5	30
139	Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification. PLoS Pathogens, 2005, 1, e6.	2.1	226
140	Identification of Human VPS37C, a Component of Endosomal Sorting Complex Required for Transport-I Important for Viral Budding. Journal of Biological Chemistry, 2005, 280, 628-636.	1.6	71
141	HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. Journal of Cell Biology, 2005, 168, 89-101.	2.3	184
142	Identification of Domains in Gag Important for Prototypic Foamy Virus Egress. Journal of Virology, 2005, 79, 6392-6399.	1.5	41
143	Matrix-Induced Inhibition of Membrane Binding Contributes to Human Immunodeficiency Virus Type 1 Particle Assembly Defects in Murine Cells. Journal of Virology, 2005, 79, 15586-15589.	1.5	25
144	Cyclophilin Interactions with Incoming Human Immunodeficiency Virus Type 1 Capsids with Opposing Effects on Infectivity in Human Cells. Journal of Virology, 2005, 79, 176-183.	1.5	180

#	Article	IF	Citations
145	Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity. Journal of Virology, 2005, 79, 15567-15572.	1.5	133
146	Human Tripartite Motif 5Î± Domains Responsible for Retrovirus Restriction Activity and Specificity. Journal of Virology, 2005, 79, 8969-8978.	1.5	223
147	Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5Â. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10774-10779.	3.3	345
148	Context-Dependent Effects of L Domains and Ubiquitination on Viral Budding. Journal of Virology, 2004, 78, 5554-5563.	1.5	129
149	Human Immunodeficiency Virus Type 1 Matrix Inhibits and Confers Cooperativity on Gag Precursor-Membrane Interactions. Journal of Virology, 2004, 78, 9560-9563.	1.5	79
150	APOBEC3G Incorporation into Human Immunodeficiency Virus Type 1 Particles. Journal of Virology, 2004, 78, 12058-12061.	1.5	264
151	Species-Specific Tropism Determinants in the Human Immunodeficiency Virus Type 1 Capsid. Journal of Virology, 2004, 78, 6005-6012.	1.5	119
152	Intrinsic immunity: a front-line defense against viral attack. Nature Immunology, 2004, 5, 1109-1115.	7.0	396
153	Capsid-Dependent and -Independent Postentry Restriction of Primate Lentivirus Tropism in Rodent Cells. Journal of Virology, 2004, 78, 1006-1011.	1.5	43
154	Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO Journal, 2003, 22, 385-394.	3.5	216
155	Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Medicine, 2003, 9, 1138-1143.	15.2	362
156	Restriction factors: a defense against retroviral infection. Trends in Microbiology, 2003, 11, 286-291.	3.5	100
157	Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12414-12419.	3.3	375
158	A Bipartite Late-Budding Domain in Human Immunodeficiency Virus Type 1. Journal of Virology, 2003, 77, 12373-12377.	1.5	55
159	Role of ESCRT-I in Retroviral Budding. Journal of Virology, 2003, 77, 4794-4804.	1.5	231
160	Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11914-11919.	3.3	261
161	Envelope-Dependent, Cyclophilin-Independent Effects of Glycosaminoglycans on Human Immunodeficiency Virus Type 1 Attachment and Infection. Journal of Virology, 2002, 76, 6332-6343.	1.5	111
162	Cyclin T1 Expression Is Mediated by a Complex and Constitutively Active Promoter and Does Not Limit Human Immunodeficiency Virus Type 1 Tat Function in Unstimulated Primary Lymphocytes. Journal of Virology, 2002, 76, 208-219.	1.5	16

#	Article	IF	Citations
163	HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nature Medicine, 2001, 7, 1313-1319.	15.2	676
164	Multiple Blocks to Human Immunodeficiency Virus Type 1 Replication in Rodent Cells. Journal of Virology, 2000, 74, 9868-9877.	1.5	176
165	Functional Differences between Human and Bovine Immunodeficiency Virus Tat Transcription Factors. Journal of Virology, 2000, 74, 4666-4671.	1.5	3
166	Role Of Chemokine Receptors In Hiv-1 Infection And Pathogenesis. Advances in Virus Research, 1999, 52, 233-267.	0.9	27
167	Highly Divergent Lentiviral Tat Proteins Activate Viral Gene Expression by a Common Mechanism. Molecular and Cellular Biology, 1999, 19, 4592-4599.	1.1	40
168	Analysis of the Effect of Natural Sequence Variation in Tat and in Cyclin T on the Formation and RNA Binding Properties of Tat-Cyclin T Complexes. Journal of Virology, 1999, 73, 5777-5786.	1.5	35
169	Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO Journal, 1998, 17, 7056-7065.	3.5	245
170	Multiple Residues Contribute to the Inability of Murine CCR-5 To Function as a Coreceptor for Macrophage-Tropic Human Immunodeficiency Virus Type 1 Isolates. Journal of Virology, 1998, 72, 1918-1924.	1.5	71
171	Sequences in <i>pol</i> Are Required for Transfer of Human Foamy Virus-Based Vectors. Journal of Virology, 1998, 72, 5510-5516.	1.5	51
172	No Evidence of Antibody to Human Foamy Virus in Widespread Human Populations. AIDS Research and Human Retroviruses, 1996, 12, 1473-1483.	0.5	61
173	A Comparative Study of Higher Primate Foamy Viruses, Including a New Virus from a Gorilla. Virology, 1995, 207, 217-228.	1.1	88
174	Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID). Journal of Medical Virology, 1994, 43, 28-32.	2.5	4